Skip to main content

Day: January 30, 2024

AURI Token Listing and Partnership With a Top 100 CoinMarketcap Exchange

Written by Customer Service on . Posted in Public Companies.

AURI Token Listing on Global Exchange DALLAS, TX, Jan. 30, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Auri Inc. (OTCPK: “AURI”) (the “Company”) Today, AURI the company is proud to announce a partnership and listing on Salavi Exchange. AURI Inc. has been informed that the listing will take place at 10 am UDT on January 30, 2024. This listing will allow the AURI Token to be traded on a CEX with USDT pairing. This will allow for an increased market exposure and help grow the AURI Token Project, Both Salavi and AURI have agreed to post information pertaining to the partnership and conduct airdrops throughout this partnership, AURI Inc. is excited for where this partnership will lead. Our experience has been stellar with Salavi. Their customer Service, knowledge and expertise has been incredible. We look forward to the next steps of...

Continue reading

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

Written by Customer Service on . Posted in Public Companies.

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in almost a decade — — Fruquintinib already approved in mainland China, Macau SAR and the United States — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMED”) today announces that the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). ELUNATE® is a selective oral inhibitor of vascular endothelial growth...

Continue reading

Check Point Software Unveils New Partner Program to Maximize Partners’ Potential and Drive Growth

Written by Customer Service on . Posted in Public Companies.

New program streamlines tiering structure, with transparent pricing, cumulative discounts, and elevated deal registration incentives for valued partners BANGKOK, Thailand, Jan. 29, 2024 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading AI-powered, cloud-delivered cyber security platform provider, today announced the launch of its innovative new Partner Program. Amidst an ever-evolving cyber security landscape, this program aims to strengthen partner capabilities and fuel growth. The cyber security sector is experiencing rapid growth and transformation. According to Canalys, cyber security spending hit $19 billion recently, reflecting the increasing need for collaborative security solutions. As technology evolves, so too do cyber threats, prompting an increased need for a unified cyber security...

Continue reading

Non Airbreathing Propulsion System Market Size Worth USD 8.70 Billion in 2032 | Emergen Research

Written by Customer Service on . Posted in Mergers And Acquisitions.

Increasing commercial application of non-airbreathing propulsion systems is a key factor driving global non-airbreathing propulsion system market revenue growth Vancouver, Jan. 29, 2024 (GLOBE NEWSWIRE) — The global non-airbreathing propulsion system market size was USD 5.07 Billion in 2022 and is expected to register a rapid revenue CAGR of 5.5% during the forecast period. Increasing commercial application of non-airbreathing propulsion systems, such as rocket propulsion system, nuclear propulsion, and electric propulsion systems, is a key factor driving market revenue growth. Demand for such propulsion systems is rising as these systems consume less fuel than conventional systems while producing less noise and vibration. High efficiency offered by non-airbreathing propulsion systems and rapid technological advancements in these...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.